This review discusses recent progress in developing treatments for pulmonary arterial hypertension aimed at prolonging life and improving quality of life.
Answers are grounded in this paper and cite their sources.
Emerging PAH therapies may extend survival and QoL; leaves open optimal sequencing and long-term comparative efficacy.
Pulmonary arterial hypertension, which is characterized by vascular proliferation and remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary vascular resistance and, ultimately, to right ventricular failure and death. Despite recent major improvements in therapy, no current treatments cure this devastating condition. This article discusses recent progress in developing treatments that prolong patients' lives and improve their quality of life.
No takes yet. Share an insight, caveat, or question.
Humbert et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: